JAMA Ophthalmology : Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema

JAMA Network - Ein Podcast von The JAMA Network

Podimo 45 Tage kostenlos testen

Ein Universum voller exklusiver Podcasts und Hörbücher. Klicken Sie hier um loszulegen!

Werbung

Interview with David W. Hutton, PhD, author of Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. Hosted by Neil Bressler, MD.

Visit the podcast's native language site